Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection
“We expect that the IMO-2125 trial with ribavirin in treatment-naïve HCV
patients and our ongoing IMO-2125 monotherapy trial in HCV patients who
failed to respond to previous standard of care therapy will provide us
with data in two HCV patient populations on safety, immunological
activity, and effect on HCV RNA levels,” said
About the Trial
The phase 1 randomized, placebo-controlled clinical trial evaluating
IMO-2125 in combination with ribavirin is being conducted in
treatment-naïve patients with genotype 1 chronic HCV infection. IMO-2125
is administered subcutaneously once a week for four weeks in combination
with daily oral administration of standard doses of ribavirin. The
target enrollment is 15 patients per cohort, with 12 randomized to
receive IMO-2125 plus ribavirin treatment and three randomized to
receive placebo plus ribavirin treatment. The primary objective of the
trial is to assess the safety and tolerability of IMO-2125 over an
escalating range of dosages in combination with standard doses of
ribavirin. In addition, the effect of treatment on HCV RNA levels will
be monitored. The clinical trial is expected to be conducted at five or
more sites in
Upcoming Presentations on IMO-2125 at the 60th
Annual Meeting of the
The Company’s two abstracts have been published and can be accessed on the AASLD website. The abstracts are:
- Abstract 1593: “IMO-2125, a TLR9 agonist, induces Th-1 type cytokines and interferons with potent anti-HCV activity in human peripheral blood mononuclear cells and plasmacytoid dendritic cells”
- Abstract 1597: “Gene expression profiles induced by IMO-2125, an agonist of Toll-like receptor 9, in human peripheral blood mononuclear cells”
The posters will be presented on
About IMO-2125
IMO-2125 is a novel DNA-based TLR9 agonist being evaluated for the treatment of chronic HCV infection. IMO-2125 was designed to induce endogenous interferon-alpha along with other immune response factors to treat hepatitis C. In preclinical studies, the immune response factors induced by IMO-2125 have potent activity alone and in combination with ribavirin in HCV replicon assays. In addition to the announced trial, IMO-2125 is also being evaluated as a monotherapy in an ongoing phase 1 randomized, placebo-controlled clinical trial for the treatment of patients with chronic HCV infection who have failed to respond to previous standard of care combination therapy of ribavirin and pegylated interferon-alpha.
About the IMO-2125 Monotherapy Trial
In this trial, IMO-2125 is administered subcutaneously once a week with four weeks of treatment. The target enrollment is ten patients per cohort, with eight randomized to receive IMO-2125 treatment and two randomized to receive placebo treatment. The trial is designed to assess the safety and tolerability of IMO-2125 over an escalating range of dose levels and to determine the effect of IMO-2125 on HCV RNA levels and parameters of immune system activation. The trial is being conducted at six U.S. sites.
About
Idera Forward Looking Statements
This press release contains forward-looking statements concerning
Source:
Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com